A5102834877- Mesenchymal stem cell research
- Cancer Cells and Metastasis
- Inflammatory Bowel Disease
- Biomarkers in Disease Mechanisms
- Neurogenesis and neuroplasticity mechanisms
- Effects of Radiation Exposure
- Radiation Therapy and Dosimetry
- Hydrogen's biological and therapeutic effects
- Ultrasound and Hyperthermia Applications
- Digestive system and related health
- Anesthesia and Neurotoxicity Research
- Neonatal Respiratory Health Research
- Medical and Biological Sciences
- Free Radicals and Antioxidants
- bioluminescence and chemiluminescence research
- Tissue Engineering and Regenerative Medicine
- Circadian rhythm and melatonin
- Electron Spin Resonance Studies
- Nuclear Physics and Applications
- Nitric Oxide and Endothelin Effects
- Advanced Radiotherapy Techniques
- Hematopoietic Stem Cell Transplantation
- Redox biology and oxidative stress
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Hemoglobin structure and function
Medical Radiological Research Center
2005-2020
Ministry of Health of the Russian Federation
2012-2018
Federal State Budgetary Scientific Institution Research Institute of Medical Primatology
2018
Monash University
2016
Russian Academy of Sciences
1997-2011
Academy of Medical Sciences
1997-2011
Central Research Institute of Epidemiology
2011
Research Institute of Medical Genetics of Russian Academy of Medical Sciences
2006
To evaluate the effectiveness of MSCs therapy in patients with CD receiving azathioprine (AZA).The study included 34 inflammatory (luminal) form CD. The 1st group (n=15) received an- ti-inflammatory using culture combination AZA. 2nd (n=19) without severity attack was assessed points accordance Crohn's disease activity index (CDAI). Immunoglobulins (IgA, IgG, IgM), interleukins (IL) 1β, 4, 10, tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), transforming growth factor-1β (TGF-1β),...
Numerous studies have shown that mesenchymal stromal cells (MSCs) a high potential for differentiation and immunosuppressive properties. Currently under phases I–III clinical trials evaluating the efficacy safety of MSCs in treatment patients with inflammatory bowel disease (IBD) –ulcerative colitis (UC) Crohn's (CD). To compare frequency relapses duration remission 5 years follow-up luminal (CD) total defeat ulcerative receiving therapy bone marrow. We compared form CD (colitis ileokolit),...
Background: Transplantation of mesenchymal stem cells (MSCs) is one the most promising directions in treatment idiopathic pulmonary fibrosis. In experimental small animal studies, intravenous and endobronchial (installation) techniques are used for cell preparation delivery, while humans inhalation drugs simplest available method.
 Aim: The aim study was to determine optimal type a nebulizer viability MSCs during nebulization, followed by comparison effects delivery methods standard...
One of the predictors relapse-free course Crohn's disease (CD) is a complete healing intestinal mucosa. Anticytokine therapy with anti-TNF-α drugs contributes to clinical and endoscopic remission CD. promising new therapies also CD cell mesenchymal stem cells (MSCs) bone marrow. In some cases, together MSC, patients received concomitant immunosuppressive therapy. It found that immunomodulatory (azathioprine, methotrexate, 6-mercaptopurine, infliximab), regardless concentration, do not affect...
Background: One of the predictors relapse-free course Crohn's disease (CD) is a complete healing intestinal mucosa.Anticytokine therapy with anti-TNF-α drugs contributes to clinical and endoscopic remission CD.One promising new therapies also CD cell mesenchymal stem cells (MSC) bone marrow.In some cases, together MSC, patients receiving concomitant immunosuppressive therapy.It found that immunomodulatory (azathioprine, methotrexate, 6-mercaptopurine, infliximab), regardless concentration,...
Restoration of damaged tissue and correction gut immunologic disorders at the same time can be achieved this stage medical science only cell therapy. development optimal schemes introducing culture mesenchymal stromal cells (MSCs) to increase effectiveness anti-inflammatory therapy ulcerative colitis (UC). There were three groups patients with UC chronic continuous relapsing course: I-I group (n=15), which MSCs administered times a month an interval 1 week, II-I (n=20) MBC received single...